- Went public (BIOV), Jul 2006
- Raised $8M funding round, Jul 2006
- Raised $330k funding round, Apr 2010
About
BioView develops, manufactures, and markets automated cell-imaging and analysis solutions for use in cytology, cytogenetic, pathology, clinical, and research laboratories. The company's products include a wide range of FDA-cleared clinical applications as well as web review and analysis solutions.
BioView's proprietary imaging, analysis, and review technology automatically controls fully motorized fluorescent and bright-field microscopes equipped with high-resolution cameras. This automates the review, analysis, and reporting processes and reduces laboratories' turnaround time on labor-intensive tests.
BioView's DUET imaging and analysis platform has received FDA clearance for several FISH applications for cancer detection and diagnosis and detection of genetic aberrations. BioView products have CE marking, as well as a Korean, Australian, and Thai FDA approval. The company is continually expanding its regulatory approval reach to additional countries.
The company is currently developing and plans to market its proprietary, self-developed test for noninvasive early detection of lung cancer, combining a biological test kit and BioView's unique Target FISH application.
Funding history · 2 rounds · $8.3M total
Q&A
- What is BioView's primary business?
- BioView develops, manufactures, and markets automated cell-imaging and analysis solutions for use in cytology, cytogenetic, pathology, clinical, and research laboratories.
- When was BioView founded?
- BioView was founded in August 1998.
- What is BioView's total funding to date?
- BioView has raised a total of $8.33 million USD.
- When did BioView go public?
- BioView went public on the TASE in July 2006, raising $8 million USD.
- What is BioView's market capitalization?
- BioView's market capitalization is $7,151,057 USD.
- Where is BioView's headquarters located?
- BioView's headquarters is located in Rehovot, Israel.
- What regulatory clearances has BioView's DUET platform received?
- BioView's DUET imaging and analysis platform has received FDA clearance for several FISH applications for cancer detection and diagnosis and detection of genetic aberrations.
- What new product is BioView currently developing?
- BioView is currently developing a proprietary, self-developed test for noninvasive early detection of lung cancer, combining a biological test kit and BioView's unique Target FISH application.
Team · 3
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | bioview.com/ |
|---|---|
| linkedin.com/company/80102 | |
| facebook.com/BioViewInc |
Identifiers & details
| Founded | 1998-8 |
|---|---|
| Employees (exact) | 37 |
| Offices | USA |
| Market cap | $7.2M |
| Status reason | Public on TASE on Jul, 2006 |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| 2006-07 | BIOV | $8.0M |
Radar intelligence
Patents
| EPO | 9 |
|---|
Publications (Crossref)
| Works | 10 |
|---|
GitHub
| Top repos | bioview-common |
|---|
Web history (Wayback)
| Domain | bioview.com |
|---|
Certificate / subdomain footprint
| Subdomains | 17 |
|---|